Opinion|Videos|November 20, 2026

Initiating Capivasertib and Managing Early Toxicities in HR+/HER2-Negative Advanced Breast Cancer

Dr. Paolo Tarantino reviews the initiation of capivasertib plus fulvestrant in the hypothetical patient, including the standard capivasertib dose of 400 mg orally twice daily on a 4-days-on, 3-days-off schedule.

Dr. Paolo Tarantino reviews the initiation of capivasertib plus fulvestrant in the hypothetical patient, including the standard capivasertib dose of 400 mg orally twice daily on a 4-days-on, 3-days-off schedule. He emphasizes documenting baseline fasting glucose and HbA1c, educating the patient about potential adverse events, and providing written instructions and antidiarrheal medication before treatment begins. He discusses early toxicity management, including a grade 2 pruritic rash during week 2, which improves following a temporary treatment interruption, oral antihistamine, and topical corticosteroid. The patient's diarrhea is managed with loperamide. Dr. Tarantino then addresses glucose monitoring and the development of asymptomatic hyperglycemia at week 4, when the patient's fasting plasma glucose reaches 186 mg/dL. He explains the need to withhold capivasertib until glucose improves, noting that treatment can be resumed at the same dose after the patient's level decreases to 148 mg/dL. He also discusses metformin as an option for managing treatment-related hyperglycemia and the potential need for dose reduction if glucose recovery takes longer than 4 weeks.


Related to this article

FDA Removes PCNSL Limitation From Liso-Cel Label
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.